On September 23, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29, 2021 (Press release, Scopus BioPharma, SEP 23, 2021, View Source [SID1234590205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology. Scopus announced the launch of Duet on September 2, 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting on behalf of the company. Dr. Horsager’s presentation will be part of the Green Track on Wednesday, September 29, 2021. The presentation will be streamed live beginning at 4:20 PM EST and will be accessible by clicking here.

If you are an institutional investor interested in scheduling a one-on-one meeting with the company, please click here to register for the conference and request a one-on-one meeting.

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

• RNA silencing CpG-STAT3siRNA ("DUET-01")

• Antisense CpG-STAT3ASO ("DUET-02")

• DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")

DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

On September 23, 2021 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that Chief Executive Officer, Zachary Hornby, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021, from 1:20-1:50 p.m. ET (Press release, Boundless Bio, SEP 23, 2021, View Source [SID1234590227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 23, 2021 bioAffinity Technologies, a privately held biotech company, reported that the Australian Patent Office issued a Notice of Acceptance for bioAffinity subsidiary OncoSelect’s patent protecting compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs (Press release, BioAffinity Technologies, SEP 23, 2021, View Source [SID1234590228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"bioAffinity is focused on being the leader in research, development and commercialization of porphyrin-based diagnostics and therapeutics to detect cancer early and treat cancer specifically"

The patent, titled "Porphyrin Compounds and Compositions Useful for Treating Cancer," will be the Company’s first awarded therapeutic patent. In addition to the Australian patent, bioAffinity and its subsidiary OncoSelect have 18 patent applications filed to protect therapeutic discoveries. bioAffinity also holds 17 awarded patents and eight patent applications related to its porphyrin-based diagnostic platform.

"bioAffinity is focused on being the leader in research, development and commercialization of porphyrin-based diagnostics and therapeutics to detect cancer early and treat cancer specifically," said bioAffinity President and CEO Maria Zannes. "We successfully developed our highly accurate CyPath Lung test for the early detection of lung cancer. Our test is based on the fluorescent porphyrin TCPP’s remarkable ability to bind to cancer and cancer-associated cells that can be detected by flow cytometry using automated analysis."

bioAffinity’s research to support the CyPath diagnostic platform has led to multiple discoveries related to cancer therapeutics, including use of novel compositions to attach chemotherapy drugs to porphyrins for targeted delivery into the tumor cell, with a much less deleterious effect on normal cells. Yet another discovery has led to the successful use of RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells.

"We have built upon our diagnostic research to develop a diverse number of targeted therapeutics and provide novel life-saving strategies in the fight against cancer," Zannes said. "The Notice of Acceptance of this patent application not only protects our groundbreaking discoveries but also validates the strength of our science."

On September 23, 2021 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that management will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021 at 3:20 p.m. EDT (Press release, IGM Biosciences, SEP 23, 2021, View Source [SID1234590243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On September 23, 2021 Revitope Oncology, Inc. is a privately owned company in Cambridge, MA, reported that focuses on the development of next-generation T cell engager immunotherapies for a variety of solid cancer indications (Press release, Revitope Oncology, SEP 23, 2021, View Source [SID1234591881]). Revitope’s platform is a suite of proprietary and modular bispecific antibodies designed to deliver improved therapeutic efficacy and safety through built-in control mechanisms that enable exquisite tumor-specificity. The company has several cancer programs in preclinical development and expects to have its lead program in the clinic by early 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!